ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

ImmunityBio Inc. (NASDAQ:IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.Anktiva Trial UpdateThe company on Friday said enrollment exceeded internal expectations in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005.Enrollment is now over 85% complete, with full enrollment of the planned study population anticipated by the second quarter of 2026.Based on the current enrollment trajecto ...